HC Wainwright & Co. Downgrades Intercept Pharma to Sell, Lowers Price Target to $8
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce downgraded Intercept Pharma (NASDAQ:ICPT) from Neutral to Sell and lowered the price target from $14 to $8.
May 22, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intercept Pharma downgraded to Sell by HC Wainwright & Co. with a lowered price target of $8.
The downgrade from Neutral to Sell and the lowering of the price target from $14 to $8 by HC Wainwright & Co. analyst Ed Arce indicates a negative outlook for Intercept Pharma. This could lead to a short-term decline in the stock price as investors may react to the new rating and price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100